Johnson & Johnson Record High Rally Has Further to Run on Drug Pipeline Strength, UBS Anal

The Quick Take

• Johnson & Johnson shares at record highs with UBS and Jim Cramer both saying the rally still has room to run
• Strong pharmaceutical pipeline and medical device segment recovery cited as key drivers for J&J continued outperformance
• J&J's diversified healthcare model — spanning pharma, MedTech, and consumer spinoff — provides multiple earnings growth levers
• Record high valuations reflect market confidence in J&J's post-Kenvue spinoff capital allocation and dividend growth strategy

Johnson & Johnson shares have hit record highs, with UBS maintaining a bullish stance on the healthcare giant and Jim Cramer agreeing on CNBC that the rally still has significant room to run. The UBS view centers on J&J's pharmaceutical pipeline strength, particularly oncology and immunology assets that can sustain double-digit earnings growth well beyond current consensus estimates. J&J's successful spinoff of Kenvue (the consumer health business) in 2023 has streamlined the corporate structure and is increasingly credited for allowing management to focus capital deployment on higher-margin pharmaceutical and MedTech assets.

J&J's MedTech segment, which sells surgical robots, orthopedic implants, and cardiovascular devices, has recovered strongly from the pandemic-era procedure backlog. Margin expansion in MedTech combined with continued pharmaceutical growth creates a rare combination of defensive characteristics and growth optionality that institutional investors find compelling. The record high share price also reflects confidence in J&J's ability to navigate ongoing Talc litigation, which has been a major overhang for years. Settlement progress on talc removes a key risk discount from J&J's valuation multiple.

Monitor J&J's next quarterly earnings for specific pharmaceutical revenue figures — particularly Darzalex (multiple myeloma) and Tremfya (immunology) which are the key commercial pipeline drivers. Watch the UBS price target and model assumptions for any revisions following the next earnings print. Talc litigation settlement progress is the key risk variable: any adverse court ruling would likely reverse the record high momentum, while final settlement resolution would add further multiple expansion upside.

Synthesized from 1 source.